153 related articles for article (PubMed ID: 19835018)
21. The effect of federal and state off-label marketing investigations on drug prescribing: The case of olanzapine.
Wang B; Studdert DM; Sarpatwari A; Franklin JM; Landon J; Kesselheim AS
PLoS One; 2017; 12(4):e0175313. PubMed ID: 28388667
[TBL] [Abstract][Full Text] [Related]
22. Injecting Safety into Supplements - Modernizing the Dietary Supplement Law.
Cohen PA; Bass S
N Engl J Med; 2019 Dec; 381(25):2387-2389. PubMed ID: 31851798
[No Abstract] [Full Text] [Related]
23. The limits of free speech.
Nature; 2012 Dec; 492(7429):311. PubMed ID: 23281497
[No Abstract] [Full Text] [Related]
24. Pharmaceuticals and medical devices: FDA oversight.
; Berry MD
Issue Brief Health Policy Track Serv; 2012 Jan; ():1-86. PubMed ID: 22403845
[No Abstract] [Full Text] [Related]
25. US lawmakers tackle safety reforms at the FDA.
Zwillich T
Lancet; 2007 Jun; 369(9578):1989-90. PubMed ID: 17577942
[No Abstract] [Full Text] [Related]
26. Congress, the FDA, and the fair development of new medications for children.
McKinney RE
Pediatrics; 2003 Sep; 112(3 Pt 1):669-70. PubMed ID: 12949299
[No Abstract] [Full Text] [Related]
27. FDA targets unapproved drugs.
Young D
Am J Health Syst Pharm; 2007 Feb; 64(4):347-8. PubMed ID: 17299170
[No Abstract] [Full Text] [Related]
28. PLIVA v. Mensing: generic consumers' unfortunate hand.
Lee SB
Yale J Health Policy Law Ethics; 2012; 12(2):209-63. PubMed ID: 23175916
[No Abstract] [Full Text] [Related]
29. Pharmaceuticals and medical devices: FDA oversight. Issue brief.
Berry MD
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-79. PubMed ID: 23297449
[No Abstract] [Full Text] [Related]
30. A Citizen's Pathway Gone Astray - Delaying Competition from Generic Drugs.
Feldman R; Wang C
N Engl J Med; 2017 Apr; 376(16):1499-1501. PubMed ID: 28248550
[No Abstract] [Full Text] [Related]
31. Teaching clinicians about drugs--50 years later, whose job is it?
Avorn J
N Engl J Med; 2011 Mar; 364(13):1185-7. PubMed ID: 21449781
[No Abstract] [Full Text] [Related]
32. Doctor explains why he blew the whistle.
Petersen M
N Y Times Web; 2003 Mar; ():C1, C2. PubMed ID: 12812161
[No Abstract] [Full Text] [Related]
33. Pharmaceutical promotion and First Amendment rights.
Troy DE; Gottlieb S
N Engl J Med; 2008 Jul; 359(5):536; author reply 536-7. PubMed ID: 18669437
[No Abstract] [Full Text] [Related]
34. Presumption of innocence: FDA's authority to regulate the specifics of prescription drug labeling and the preemption debate.
Dorfman HL; Quinn VM; Brophy EA
Food Drug Law J; 2006; 61(4):585-622. PubMed ID: 17180765
[No Abstract] [Full Text] [Related]
35. Pharmaceutical promotion to physicians and First Amendment rights.
Kesselheim AS; Avorn J
N Engl J Med; 2008 Apr; 358(16):1727-32. PubMed ID: 18420505
[No Abstract] [Full Text] [Related]
36. The use of Food and Drug Administration--approved medications for unlabeled (off-label) uses. The legal and ethical implications.
Torres A
Arch Dermatol; 1994 Jan; 130(1):32-6. PubMed ID: 8285737
[TBL] [Abstract][Full Text] [Related]
37. Legal Liability of Generic vs Brand Drug Manufacturers for Inadequate Product Labels.
Boumil MM; Curfman G
JAMA; 2018 Aug; 320(6):547-548. PubMed ID: 30039167
[No Abstract] [Full Text] [Related]
38. Forbidden and Permitted Statements about Medications--Loosening the Rules.
Avorn J; Sarpatwari A; Kesselheim AS
N Engl J Med; 2015 Sep; 373(10):967-73. PubMed ID: 26332553
[No Abstract] [Full Text] [Related]
39. Bolstering the FDA's drug-safety authority.
Schultz WB
N Engl J Med; 2007 Nov; 357(22):2217-9. PubMed ID: 18046024
[No Abstract] [Full Text] [Related]
40. FDA off-track on off-label drug promotion.
Lancet; 2007 Dec; 370(9604):1976. PubMed ID: 18083382
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
